Vaxart, Inc. Contracts & Agreements

Underwriting Agreement, dated June 6, 2023, by and between Vaxart, Inc. and Cantor Fitzgerald & Co (Filed With SEC on June 8, 2023)

Amendment to Letter Agreement dated May 2, 2023 between Andrei Floroiu and Vaxart, Inc (Filed With SEC on May 4, 2023)

Amendment to the Vaxart, Inc. Severance Benefit Plan dated May 2, 2023 (Filed With SEC on May 4, 2023)

Description of Securities of the Registrant (Filed With SEC on March 15, 2023)

Offer Letter, dated December 5, 2022, by and between the Company and Phillip Lee (Filed With SEC on March 15, 2023)

Pre-Challenge Study Services Agreement dated June 29, 2022, between the Company and hVIVO Services Limited (Filed With SEC on August 8, 2022)

2019 Equity Incentive Plan (Filed With SEC on August 5, 2022)

2022 Employee Stock Purchase Plan (Filed With SEC on August 5, 2022)

CONFIDENTIAL CONSULTING AGREEMENT (Filed With SEC on May 11, 2022)

CONSULTING SERVICES AGREEMENT (Filed With SEC on May 11, 2022)

Non-Employee Director Compensation Program, effective as of April 1, 2022 (Filed With SEC on May 9, 2022)

Description of Securities of the Registrant (Filed With SEC on February 24, 2022)

Asset Purchase Agreement, dated November 24, 2021, by and between Vaxart, Inc. and Kindred Biosciences, Inc (Filed With SEC on February 24, 2022)

Offer letter, dated January 18, 2022, by and between the Company and Edward Berg (Filed With SEC on February 24, 2022)

Offer Letter, dated August 16, 2021, by and between the Company and James Cummings MD (Filed With SEC on November 4, 2021)

Lease Agreement, dated September 17, 2021, by and between Vaxart, Inc. and Britannia Pointe Grand Limited Partnership (Filed With SEC on September 21, 2021)

Second Amendment to Lease Agreement, dated September 17, 2021, by and between Vaxart, Inc. and Healthpeak Properties, Inc (Filed With SEC on September 21, 2021)

Controlled Equity OfferingSM Sales Agreement (Filed With SEC on September 16, 2021)

Vaxart, Inc. 2019 Equity Incentive Plan (as amended on April 28, 2021) (Filed With SEC on June 21, 2021)

Description of Securities of the Registrant (Filed With SEC on February 25, 2021)

Sublease Agreement dated November 16, 2020, by and between Vaxart, Inc. and Vera Therapeutics, Inc (Filed With SEC on February 25, 2021)

Master Services Agreement, dated April 17, 2020, by and between Vaxart, Inc. and Kindred Biosciences, Inc (Filed With SEC on November 12, 2020)

Statement of Work 003, dated September 11, 2020, under the Master Services Agreement, dated April 17, 2020, by and between Vaxart, Inc. and Kindred Biosciences, Inc (Filed With SEC on November 12, 2020)

Statement of Work 004, dated September 11, 2020, under the Master Services Agreement, dated April 17, 2020, by and between Vaxart, Inc. and Kindred Biosciences, Inc (Filed With SEC on November 12, 2020)

OPEN MARKET SALE AGREEMENTSM (Filed With SEC on October 14, 2020)

Separation Agreement, dated June 14, 2020, between Vaxart, Inc. and Wouter W. Latour, M.D (Filed With SEC on June 15, 2020)

Letter Agreement, dated June 14, 2020, between Vaxart, Inc. and Andrei Floroiu (Filed With SEC on June 15, 2020)

Offer Letter, dated May 1, 2006, by and between the Company and Dr. Sean Tucker (Filed With SEC on May 12, 2020)

Offer Letter, dated March 26, 2018, by and between the Company and Margaret Echerd (Filed With SEC on May 12, 2020)

Letter dated December 27, 2018, from the Company to Margaret Echerd (Filed With SEC on May 12, 2020)

Description of Securities of the Registrant (Filed With SEC on March 19, 2020)

Form of Warrant (Filed With SEC on March 2, 2020)

Form of Placement Agent Warrant (Filed With SEC on March 2, 2020)

Form of Securities Purchase Agreement, dated February 27, 2020, among the Company and the Purchasers named therein (Filed With SEC on March 2, 2020)

Underwriting Agreement (Filed With SEC on September 24, 2019)

Form of Representative Warrant (Filed With SEC on September 24, 2019)

Manufacturing Services Agreement dated July 17, 2019, by and between Vaxart, Inc. and Lonza Houston, Inc (Filed With SEC on September 24, 2019)

First Amendment to Lease Agreement dated September 17, 2019, by and between Vaxart, Inc. and HCP, Inc (Filed With SEC on September 19, 2019)

Form of Pre-Funded Warrant (Filed With SEC on September 11, 2019)

Form of Common Warrant (Filed With SEC on September 11, 2019)

Form of Representative Warrant (Filed With SEC on September 11, 2019)

2019 Equity Incentive Plan (Filed With SEC on April 24, 2019)

Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the 2019 Equity Incentive Plan (Filed With SEC on April 24, 2019)

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2019 Equity Incentive Plan (Filed With SEC on April 24, 2019)

Underwriting Agreement (Filed With SEC on April 8, 2019)

Form of Common Warrant (Filed With SEC on April 8, 2019)

Form of Representative Warrant (Filed With SEC on April 8, 2019)

Form of Securities Purchase Agreement, dated as of March 19, 2019, by and among Vaxart, Inc. and the Purchasers named therein (Filed With SEC on March 20, 2019)

Engagement Letter, dated as of January 25, 2019, by and between Vaxart, Inc. and H.C. Wainwright & Co., LLC., as amended (Filed With SEC on March 20, 2019)

Form of Placement Warrants (Filed With SEC on March 20, 2019)

Form of Pre-Funded Warrant (Filed With SEC on February 6, 2019)

Vaxart, Inc. Severance Benefit Plan Participation Notice (Filed With SEC on August 10, 2018)

Vaxart, Inc. Severance Benefit Plan (Filed With SEC on June 6, 2018)

Second Amendment to the Loan Agreement, dated February 13, 2018, between Vaxart, Inc. and Oxford Finance LLC (Filed With SEC on February 20, 2018)

Warrant issued to Oxford Finance LLC, dated February 13, 2018 (Filed With SEC on February 20, 2018)

Form of Indemnification Agreement (Filed With SEC on February 20, 2018)

Settlement Agreement, dated as of February 9, 2018, by and among Aviragen Therapeutics, Inc., Vaxart, Inc., Digirad Corporation and East Hill Management Company, LLC (Filed With SEC on February 9, 2018)

Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated as of February 7, 2018, by and among Aviragen Therapeutics, Inc., Vaxart, Inc. and Agora Merger Sub,... (Filed With SEC on February 7, 2018)

Support Agreement, dated as of February 7, 2018, by and among Aviragen Therapeutics, Inc., Vaxart, Inc., Agora Merger Sub, Inc. and SC Fund Management LLC (Filed With SEC on February 7, 2018)

Director Stock Option Grant Form (Filed With SEC on December 12, 2017)

Agreement and Plan of Merger and Reorganization, dated October 27, 2017, by and among Aviragen Therapeutics, Inc., Vaxart, Inc. and Agora Merger Sub, Inc (Filed With SEC on October 30, 2017)

Form of Support Agreement, by and between Aviragen Therapeutics, Inc., Agora Merger Sub, Inc., Vaxart, Inc. and Aviragen Therapeutics, Inc.s directors and officers (Filed With SEC on October 30, 2017)

Form of Support Agreement, by and between Aviragen Therapeutics, Inc., Agora Merger Sub, Inc., Vaxart, Inc. and certain of Vaxart, Inc.s directors, officers and stockholders (Filed With SEC on October 30, 2017)

EMPLOYEE STOCK OPTION AGREEMENT (Filed With SEC on May 8, 2017)

CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. ROYALTY INTEREST ACQUISITION AGREEMENT... (Filed With SEC on April 26, 2016)

PROTECTIVE RIGHTS AGREEMENT (Filed With SEC on April 26, 2016)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on November 2, 2015)

BIOTA PHARMACEUTICALS, INC. Common Stock (par value $0.10 per share) At Market Issuance Sales Agreement (Filed With SEC on October 2, 2015)

STOCK PURCHASE AGREEMENT by and among BIOTA PHARMACEUTICALS, INC., EACH OF THE SHAREHOLDERS OF ANACONDA PHARMA PARTY HERETO, and THE HOLDER REPRESENTATIVE Dated as of February 25,... (Filed With SEC on May 8, 2015)

Certain information contained in this document, marked by ***, is filed with the SEC pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended (Filed With SEC on May 10, 2013)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on November 14, 2012)

BIOTA PHARMACEUTICALS, INC, NON-PLAN STOCK UNITS AGREEMENT (Filed With SEC on November 14, 2012)

SUPPORT AGREEMENT (Filed With SEC on September 18, 2012)

0 ###-###-#### x (Filed With SEC on August 8, 2012)

FIRST AMENDMENT TO RIGHTS AGREEMENT (Filed With SEC on April 26, 2012)

0 ###-###-#### x (Filed With SEC on April 23, 2012)

Nabi Biopharmaceuticals and American Stock Transfer & Trust Company, LLC as Rights Agent Rights Agreement Dated as of August 25, 2011 RIGHTS AGREEMENT (Filed With SEC on August 25, 2011)

NABI BIOPHARMACEUTICALS 12276 Wilkins Avenue Rockville, Maryland 20852 Dated March 16, 2011 (Filed With SEC on March 22, 2011)

ASSET PURCHASE AGREEMENT by and between NABI BIOPHARMACEUTICALS and (Filed With SEC on November 5, 2009)

CONSULTING AGREEMENT (Filed With SEC on November 5, 2009)

NABI BIOPHARMACEUTICALS 12276 WILKINS AVENUE (Filed With SEC on May 6, 2009)

Change of Control Severance Agreement Effective as of August 21, 2007 (Filed With SEC on March 11, 2009)

FOURTH AMENDMENT TO RIGHTS AGREEMENT (Filed With SEC on August 6, 2008)

NABI BIOPHARMACEUTICALS 12276 WILKINS AVENUE (Filed With SEC on August 6, 2008)

NABI BIOPHARMACEUTICALS 12276 Wilkins Avenue (Filed With SEC on May 8, 2008)

Nabi Biopharmaceuticals 12276 Wilkins Avenue (Filed With SEC on May 8, 2008)

Nabi Biopharmaceuticals 5800 Park of Commerce Boulevard, N.W. (Filed With SEC on February 28, 2008)

TRANSITION/TERMINATION AGREEMENT BY AND BETWEEN (Filed With SEC on February 28, 2008)

MANUFACTURING SERVICES AGREEMENT Among (Filed With SEC on February 28, 2008)

[signature page follows] (Filed With SEC on December 10, 2007)

TRANSITION SERVICES AGREEMENT (Filed With SEC on December 10, 2007)

RIGHT OF FIRST NEGOTIATION/REFUSAL AGREEMENT (Filed With SEC on December 10, 2007)

ASSET PURCHASE AGREEMENT (Filed With SEC on September 11, 2007)

SECOND AMENDMENT TO RIGHTS AGREEMENT (Filed With SEC on August 2, 2007)

THIRD AMENDMENT TO RIGHTS AGREEMENT (Filed With SEC on August 2, 2007)

NABI BIOPHARMACEUTICALS 5800 Park of Commerce Boulevard, N.W. (Filed With SEC on August 2, 2007)

NABI BIOPHARMACEUTICALS 5800 PARK OF COMMERCE BOULEVARD, N.W. (Filed With SEC on August 2, 2007)

Nabi Biopharmaceuticals 5800 Park of Commerce Boulevard, N.W. (Filed With SEC on May 3, 2007)

- 2 - (Filed With SEC on May 3, 2007)

NABI BIOPHARMACEUTICALS SUMMARY OF NON-EMPLOYEE DIRECTOR FEES (Filed With SEC on March 15, 2007)

ASSET PURCHASE AGREEMENT between NABI BIOPHARMACEUTICALS (the Seller) and (Filed With SEC on March 15, 2007)

FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT (Filed With SEC on March 15, 2007)

SECOND AMENDMENT TO ASSET PURCHASE AGREEMENT (Filed With SEC on March 15, 2007)

NONCOMPETITION AND NONSOLICITATION AGREEMENT between (Filed With SEC on March 15, 2007)

Braintree Laboratories, Inc. 60 Columbian Street West Braintree, MA 02185-0929 (Filed With SEC on March 15, 2007)

SETTLEMENT AGREEMENT (Filed With SEC on November 15, 2006)

AGREEMENT (Filed With SEC on November 15, 2006)

PLASMA PURCHASE AGREEMENT (Filed With SEC on November 14, 2006)

PLASMA PURCHASE AGREEMENT AMENDMENT (Filed With SEC on November 14, 2006)

NABI BIOPHARMACEUTICALS 5800 Park of Commerce Boulevard, N.W. (Filed With SEC on August 2, 2006)

Change of Control Severance Agreement (Filed With SEC on August 2, 2006)

RELOCATION/SIGN-ON BONUS REPAYMENT AGREEMENT (Filed With SEC on August 2, 2006)

NABI BIOPHARMACEUTICALS BASE SALARY LEVELS OF EXECUTIVE OFFICERS (Filed With SEC on August 2, 2006)

DEFINITIVE CO-DEVELOPMENT & COMMERCIALIZATION AGREEMENT BETWEEN (Filed With SEC on August 2, 2006)

FRESENIUS BIOTECH GmbH AND NABI BIOPHARMACEUTICALS AGREEMENT TO DEVELOP, SUPPLY AND MARKET ATG FRESENIUS NORTH AMERICA March 30,2006 (Filed With SEC on May 5, 2006)

Exhibit A STOCK TRANSFER POWER (Filed With SEC on May 5, 2006)

2000 Equity Incentive Plan (Filed With SEC on May 5, 2006)

NABI BIOPHARMACEUTICALS (Filed With SEC on March 6, 2006)

TERMINATION AGREEMENT (Filed With SEC on March 6, 2006)

5800 PARK OFCOMMERCE BOULEVARD, N.W. BOCA RATON, FLORIDA 33487 Effective as of September 1, 2005 (Filed With SEC on October 21, 2005)

Change of Control Severance Agreement (Filed With SEC on October 21, 2005)

LEASE AGREEMENT (Filed With SEC on October 21, 2005)

NABI BIOPHARMACEUTICALS BASE SALARY LEVELS OF EXECUTIVE OFFICERS (Filed With SEC on April 25, 2005)

Nabi (Filed With SEC on March 10, 2005)

2000 Equity Incentive Plan (Filed With SEC on March 10, 2005)

Change of ControlSeverance Agreement Effective as of December 20, 2004 (Filed With SEC on March 10, 2005)

NABI BIOPHARMACEUTICALS 5800 PARK OF COMMERCE BOULEVARD, N.W. BOCA RATON, FLORIDA 33487 (Filed With SEC on March 10, 2005)

Change of ControlSeverance Agreement Effective as of May 3, 2004 (Filed With SEC on March 10, 2005)

NABI BIOPHARMACEUTICALS 5800 PARK OF COMMERCE BOULEVARD, N.W. BOCA RATON, FLORIDA 33487 (Filed With SEC on March 10, 2005)

INDEMNIFICATION AGREEMENT (Filed With SEC on March 10, 2005)

NABI BIOPHARMACEUTICALS SUMMARY OF NON-EMPLOYEE DIRECTOR FEES (Filed With SEC on March 10, 2005)

SUMMARY OF VIPMANAGEMENT INCENTIVE PLAN (Filed With SEC on March 10, 2005)

Change of ControlSeverance Agreement Effective as of April 1, 2004 (Filed With SEC on October 25, 2004)